ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2020

9:00AM-11:00AM: Abstract Number: 1226

Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK

RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

9:00AM-11:00AM: Abstract Number: 1424

Outcomes of Hospitalizations for Acute Myocardial Infarction in Patients with ANCA Associated Vasculitis from the National Inpatient Sample

Vasculitis – ANCA-Associated Poster

9:00AM-11:00AM: Abstract Number: 1390

Outcomes of Systemic Sclerosis Patients Who Were Primarily Admitted for Acute Myocardial Infarction from 2016 to 2017: Insights from the National Inpatient Sample

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 1019

Outdoor Air Pollution and Systemic Lupus Erythematosus

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1237

Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials

RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

9:00AM-11:00AM: Abstract Number: 1085

Pain in Myositis Is Associated with the Disease Activity

Muscle Biology, Myositis & Myopathies Poster

9:00AM-11:00AM: Abstract Number: 1109

Pain in Women with Knee and/or Hip Osteoarthritis Is Related to Systemic Inflammation and to Adipose Tissue Dysfunction and Distribution: A Cross-sectional Metabolic Biomarkers Cohort Study

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 1030

Pain Medication Use Among Ankylosing Spondylitis and Psoriatic Arthritis Patients Before and After Initiation of Biologic Therapy

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1000

Passive Smoking Throughout the Life Course and the Risk of Incident Rheumatoid Arthritis in Adulthood Among Women

Epidemiology & Public Health Poster III: Inflammatory Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 0991

Pathogenic, Glycolytic PD-1+ B Cells Accumulate in the Hypoxic RA Joint

B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1394

Pathway to Systemic Sclerosis: Concerning Patients’ Experiences During the Diagnostic Process

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: PP08

Patient Participation in the COVID-19 Global Rheumatology Alliance as a Model for Involving Patients from the Ground Up

Patient Perspectives Poster

9:00AM-11:00AM: Abstract Number: 1133

Patient Perceptions of Diagnosis, Tests, Treatments, Adherence and the Impact on Their Disease Understanding and Participation in Research Studies

Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1316

Patient Perceptions of Fibromyalgia Symptoms and the Overlap with Axial Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II: Extra-MSK & Comorbidities

9:00AM-11:00AM: Abstract Number: 1131

Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model

Patient Outcomes, Preferences, & Attitudes Poster II: Miscellaneous Rheumatic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].